Expand / Collapse search
Watch TV
Menu

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by Refinitiv Lipper.

Multiple Sclerosis

Novartis' Gilenya fails in study for a type of MS

By Reuters
Published | Updated
6f34a1e8-

ZURICH – Novartis AG said on Monday its drug Gilenya failed to meet its main goal in a late-stage study as a treatment for primary progressive multiple sclerosis (PPMS).

Results of the Phase III trial involving 970 people found Gilenya, also known as fingolimod, did not show a significant difference to placebo on a combination of disability measures.

There are currently no approved treatments for PPMS, a disorder of the central nervous system characterized by a steady worsening of neurologic functioning over time. It affects around 10 percent of the 2.3 million people diagnosed with multiple sclerosis worldwide.

Gilenya is already approved in the United States and Europe as a treatment for multiple sclerosis. The drug is being tested in Phase III trials as a treatment for pediatric MS and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).